L. Schwartz

发表

Efficacy and Safety of Nifedipine Coat-Core versus Amlodipine in Patients With Mild to Moderate Essential Hypertension: Comparison of 24-Hour Mean Ambulatory Diastolic Blood Pressure

S. Jungerwirth, R. Byyny, T. Shannon, 1997, Journal of cardiovascular pharmacology and therapeutics.

Similar efficacy of nitrendipine in young and elderly hypertensive patients.

J. Mehta, P. Deedwania, N. Vlachakis, 1987, The American journal of cardiology.

The efficacy and safety of once-daily nifedipine administered without food: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate hypertension

S. Glasser, S. Ripa, S. Jungerwirth, 1995 .

The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension

Adesh K. Jain, S. Glasser, T. Shannon, 1995 .

Efficacy and safety of secondary prophylactic vs. on‐demand sucrose‐formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13‐month crossover study

M. Morfini, P. Collins, A. Faradji, 2010, Journal of thrombosis and haemostasis : JTH.

Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients

G. Di Minno, I. Pabinger, J. Windyga, 2012, Thrombosis and Haemostasis.

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS

J. Windyga, S. Lalezari, U. Martinowitz, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review

J. Mahlangu, J. Windyga, S. Ahuja, 2018, Therapeutic advances in hematology.

Human recombinant DNA‐derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation

P. Mannucci, S. Arkin, R. Zimmermann, 2004, Journal of thrombosis and haemostasis : JTH.

Efficacy and Safety of Secondary Prophylactic Versus On-Demand Sucrose-Formulated Recombinant Factor VIII Treatment in Adults with Severe Hemophilia A: Results from a 13-Month Crossover Study

M. Morfini, P. Collins, A. Faradji, 2008 .

Once-Daily Monotherapy of Hypertension with Nifedipine Sustained Release (20mg to 100mg)

L. Fisher, P. Feig, J. Devane, 1992 .

The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension. Nifedipine Study Group.

S. Glasser, A. Jain, T. Shannon, 1995, Clinical therapeutics.

The efficacy and safety of once-daily nifedipine administered without food: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate hypertension. Nifedipine Study Group.

S. Glasser, S. Ripa, S. Jungerwirth, 1995, Clinical therapeutics.

The safety and efficacy of once-daily nifedipine coat-core in combination with atenolol in hypertensive patients. Adalat CC Cooperative Study Group.

P. Feig, L. Schwartz, P. P. Pettis, 1993, Clinical therapeutics.

The efficacy and safety of once-daily nifedipine coat-core in the treatment of mild-to-moderate hypertension. Adalat CC Cooperative Study Group.

P. Feig, L. Schwartz, P. P. Pettis, 1993, Clinical therapeutics.